Glycerol phenylbutyrate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Glycerol phenylbutyrate
Glycerol phenylbutyrate skeletal.svg
Clinical data
Trade namesRavicti
AHFS/Drugs.comravicti
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
ChEMBL
ECHA InfoCard100.228.552 Edit this at Wikidata
Chemical and physical data
FormulaC33H38O6
Molar mass530.651 g/mol
3D model (JSmol)

Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.[1] It is an FDA-approved prescription drug in the US.[2] It is approved for anyone over 2 months of age. It was developed by Hyperion Theraputics based on the existing drug Buphenyl, and received approval on February 1, 2013.[3] Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[4] In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.

References[edit]

  1. ^ "Archived copy". Archived from the original on 2013-03-07. Retrieved 2013-04-01.CS1 maint: Archived copy as title (link)
  2. ^ Drugs@FDA: FDA Approved Drug Products. Accessdata.fda.gov. [accessed 2018 Feb 18]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=203284
  3. ^ Herder M. Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada. Journal of Law and the Biosciences. 2016 [accessed 2018 Feb 18];3(1):158-166. DOI: 10.1093/jlb/lsv060 URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033429/
  4. ^ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". GEN.

External links[edit]